Abstract S3-4: Ten year follow-up analysis of intense dose-dense adjuvant ETC (epirubicin (E), paclitaxel (T) and cyclophosphamide (C)) confirms superior DFS and OS benefit in comparison to conventional dosed chemotherapy in high-risk breast cancer patients with ≥ 4 positive lymph nodes.

2012 ◽  
Author(s):  
V Moebus ◽  
A Schneeweiss ◽  
A du Bois ◽  
H-J Lueck ◽  
H Eustermann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Dose Dense ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer ◽  
Positive Lymph Nodes

Study of Failure Pattern Among High-Risk Breast Cancer Patients With or Without Postmastectomy Radiotherapy in Addition to Adjuvant Systemic Therapy: Long-Term Results From the Danish Breast Cancer Cooperative Group DBCG 82 b and c Randomized Studies

2006 ◽  
Vol 24 (15) ◽  
pp. 2268-2275 ◽  
Author(s):  
Hanne M. Nielsen ◽  
Marie Overgaard ◽  
Cai Grau ◽  
Anni R. Jensen ◽  
Jens Overgaard
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Disease Recurrence ◽  
Breast Cancer Patients ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

Purpose Postmastectomy radiotherapy (RT) in high-risk breast cancer patients can reduce locoregional recurrences (LRRs) and improve disease-free and overall survival. The aim of this analysis was to examine the overall disease recurrence pattern among patients randomly assigned to receive treatment with or without RT. Patients and Methods A long-term follow-up was performed among the 3,083 patients from the Danish Breast Cancer Cooperative Group 82 b and c trials, except in those already recorded with distant metastases (DM) or contralateral breast cancer (CBC). The end points were LRR, DM, and CBC, and the follow-up continued until DM, CBC, emigration, or death. Information was selected from medical records, general practitioners, and the National Causes of Death Registry. The median potential follow-up time was 18 years. Results The 18-year probability of any first breast cancer event was 73% and 59% (P < .001) after no RT and RT, respectively (relative risk [RR], 0.68; 95% CI, 0.63 to 0.75). The 18-year probability of LRR (with or without DM) was 49% and 14% (P < .001) after no RT and RT, respectively (RR, 0.23; 95% CI, 0.19 to 0.27). The 18-year probability of DM subsequent to LRR was 35% and 6% (P < .001) after no RT and RT, respectively (RR, 0.15; 95% CI, 0.11 to 0.20), whereas the probability of any DM was 64% and 53% (P < .001) after no RT versus RT, respectively (RR, 0.78; 95% CI, 0.71 to 0.86). Conclusion Postmastectomy RT changes the disease recurrence pattern in high-risk breast cancer patients; fewer patients have LRR as first site of recurrence, and overall fewer patients have DM.

scholarly journals Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

2014 ◽  
Vol 106 (5) ◽  
Author(s):  
Brigitte Rack ◽  
Christian Schindlbeck ◽  
Julia Jückstock ◽  
Ulrich Andergassen ◽  
Philip Hepp ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Breast Cancer Patients ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

scholarly journals Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21

2007 ◽  
Vol 13 (10) ◽  
pp. 2977-2985 ◽  
Author(s):  
Teresa A. Gilewski ◽  
Govind Ragupathi ◽  
Maura Dickler ◽  
Shemeeakah Powell ◽  
Sonal Bhuta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

Mobilization of Peripheral Blood Stem Cells with Paclitaxel and rhG-CSF in High-Risk Breast Cancer Patients

2002 ◽  
Vol 11 (2) ◽  
pp. 415-421 ◽  
Author(s):  
Kenneth R. Meehan ◽  
Rebecca Slack ◽  
Edmund Gehan ◽  
Herbert B. Herscowitz ◽  
Ellen M. Areman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
High Risk ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Peripheral Blood Stem Cells ◽  
Blood Stem Cells ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

scholarly journals Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Hikmat Abdel-Razeq ◽  
Amal Al-Omari ◽  
Farah Zahran ◽  
Banu Arun
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Brca2 Mutations ◽  
Brca1 Brca2 ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document